NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
NEXGEL (NASDAQ: NXGL) has appointed Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. McGuire, who brings over 30 years of financial and public company experience, has been consulting with NEXGEL since September 2, 2024. He previously served as CFO for several private and public companies in healthcare, financial services, and manufacturing sectors, and was instrumental in guiding a biotech company to NYSE listing in July 2022.
The current CFO, Adam E. Drapczuk III, will transition to a consulting role with the company through his firm, Achieving Consulting Excellence, McGuire, a former Price Waterhouse CPA and Notre Dame graduate, will lead NEXGEL's finance functions as part of the executive management team. The appointment comes as NEXGEL, a provider of medical and OTC hydrogel products, continues to experience high growth.
NEXGEL (NASDAQ: NXGL) ha nominato Joseph F. McGuire come Chief Financial Officer, con effetto dal 1 gennaio 2025. McGuire, che porta con sé oltre 30 anni di esperienza nel settore finanziario e nelle aziende quotate, sta collaborando con NEXGEL dal 2 settembre 2024. In precedenza ha ricoperto il ruolo di CFO in diverse aziende private e pubbliche nei settori della salute, dei servizi finanziari e della produzione, ed è stato fondamentale nel guidare un'azienda biotech verso la quotazione in NYSE nel luglio 2022.
Il CFO attuale, Adam E. Drapczuk III, passerà a un ruolo di consulenza con l'azienda attraverso la sua società, Achieving Consulting Excellence. McGuire, ex CPA di Price Waterhouse e laureato alla Notre Dame, guiderà le funzioni finanziarie di NEXGEL come parte del team di gestione esecutiva. Questa nomina arriva mentre NEXGEL, fornitore di prodotti idrogel medici e OTC, continua a registrare una forte crescita.
NEXGEL (NASDAQ: NXGL) ha nombrado a Joseph F. McGuire como Director Financiero, con efecto a partir del 1 de enero de 2025. McGuire, que aporta más de 30 años de experiencia en finanzas y empresas públicas, ha estado asesorando a NEXGEL desde el 2 de septiembre de 2024. Anteriormente se desempeñó como CFO en varias empresas privadas y públicas en los sectores de salud, servicios financieros y manufactura, y fue fundamental para guiar a una empresa biotecnológica a su cotización en la NYSE en julio de 2022.
El actual CFO, Adam E. Drapczuk III, pasará a un rol de consultoría con la empresa a través de su firma, Achieving Consulting Excellence. McGuire, ex CPA de Price Waterhouse y graduado de Notre Dame, liderará las funciones financieras de NEXGEL como parte del equipo de gestión ejecutiva. Este nombramiento llega en un momento en que NEXGEL, proveedor de productos hidrogeles médicos y OTC, continúa experimentando un alta crecimiento.
NEXGEL (NASDAQ: NXGL)는 Joseph F. McGuire를 2025년 1월 1일부터 최고재무책임자(CFO)로 임명했습니다. McGuire는 30년 이상의 금융 및 상장 기업 경험을 보유하고 있으며, 2024년 9월 2일부터 NEXGEL과 컨설팅을 진행해왔습니다. 이전에는 의료, 금융 서비스 및 제조 분야의 여러 사기업 및 상장 기업에서 CFO를 역임했으며, 2022년 7월 NYSE 상장을 유도하는 데 중요한 역할을 했습니다.
현재 CFO인 Adam E. Drapczuk III는 자신의 회사인 Achieving Consulting Excellence를 통해 회사와 함께 컨설팅 역할로 전환합니다. 이전 Price Waterhouse CPA이자 노틀담 대학 졸업생인 McGuire는 경영진 팀의 일원으로 NEXGEL의 재무 기능을 이끌 것입니다. 이 임명은 의료 및 OTC 하이드로겔 제품을 제공하는 NEXGEL이 계속해서 높은 성장을 경험하고 있는 가운데 이루어졌습니다.
NEXGEL (NASDAQ: NXGL) a nommé Joseph F. McGuire au poste de Directeur Financier, prenant effet le 1er janvier 2025. McGuire, qui possède plus de 30 ans d'expérience dans la finance et au sein d'entreprises publiques, collabore avec NEXGEL depuis le 2 septembre 2024. Auparavant, il a été CFO de plusieurs entreprises privées et publiques dans les secteurs de la santé, des services financiers et de la fabrication, et a joué un rôle clé dans la guidage d'une entreprise biotech vers son introduction à la NYSE en juillet 2022.
Le CFO actuel, Adam E. Drapczuk III, passera à un rôle de consultant auprès de la société à travers sa firme, Achieving Consulting Excellence. McGuire, ancien CPA chez Price Waterhouse et diplômé de Notre Dame, dirigera les fonctions financières de NEXGEL en tant que membre de l'équipe de direction. Cette nomination intervient alors que NEXGEL, fournisseur de produits hydrogel médicaux et OTC, continue d'enregistrer une forte croissance.
NEXGEL (NASDAQ: NXGL) hat Joseph F. McGuire zum Chief Financial Officer ernannt, der am 1. Januar 2025 in Kraft tritt. McGuire bringt über 30 Jahre Erfahrung im Finanzbereich und im Management börsennotierter Unternehmen mit und berät NEXGEL seit dem 2. September 2024. Zuvor war er CFO mehrerer privater und öffentlicher Unternehmen in den Bereichen Gesundheitswesen, Finanzdienstleistungen und Fertigung und spielte eine entscheidende Rolle bei der Unterstützung eines Biotech-Unternehmens auf dem Weg zur NYSE-Notierung im Juli 2022.
Der derzeitige CFO, Adam E. Drapczuk III, wird durch seine Firma Achieving Consulting Excellence in eine Beratungsrolle bei dem Unternehmen wechseln. McGuire, ein ehemaliger CPA von Price Waterhouse und Absolvent der Notre Dame, wird als Teil des Führungsteams die Finanzfunktionen von NEXGEL leiten. Die Ernennung erfolgt zu einem Zeitpunkt, an dem NEXGEL, Anbieter von medizinischen und OTC-Hydrogelprodukten, weiterhin ein starkes Wachstum verzeichnet.
- Appointment of CFO with over 30 years of financial and public company experience
- Previous CFO remains as consultant, ensuring smooth transition
- New CFO has proven IPO experience, having led a biotech company to NYSE listing
- Company reports experiencing high growth
- None.
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant.
Adam Levy, Chief Executive Officer, stated, “As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operations and finance. Joe brings many decades of public company and financial experience that will be invaluable during this critical juncture in our company history.”
Mr. Levy continued, “I would like to thank Adam Drapczuk for his invaluable contributions to NEXGEL’s progress and success. We wish him good luck as he builds his own consulting business through Achieving Consulting Excellence, LLC, and are pleased that we can still rely on him moving forward.”
Mr. McGuire has over 30 years of financial and public company experience, having served as Chief Financial Officer for several privately held and publicly traded companies in the health care, financial services, investment, and manufacturing industries. He was a key member of the team that successfully guided a biotechnology company through its IPO, resulting in its listing on the NYSE in July 2022. In these roles, Mr. McGuire’s responsibilities included SEC financial reporting, investor relations, corporate governance, legal and audit liaison, and team building. He began his career with Price Waterhouse, where he was a certified public accountant, and later held management positions with Dean Witter Reynolds and Paine Webber, Inc. Mr. McGuire received a Bachelor of Science in accounting from the University of Notre Dame. Mr. McGuire has consulted with NEXGEL since September 2, 2024, and will serve on the executive management team to lead the Company’s finance functions.
Mr. McGuire, newly appointed Chief Financial Officer of NEXGEL, commented, “It is an exciting time to be part of NEXGEL. Adam Levy and his team have executed consistently and exceeded the markets expectations. I look forward to working with him, Adam Drapczuk and the rest of the team going forward.”
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2023, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
NEXGEL@KCSA.com
FAQ
When does Joseph McGuire start as NEXGEL's (NXGL) new CFO?
What is Joseph McGuire's experience before joining NEXGEL (NXGL)?
What happens to NEXGEL's (NXGL) previous CFO Adam Drapczuk?
How long has Joseph McGuire been associated with NEXGEL (NXGL)?
What is NEXGEL's (NXGL) current business performance status?
